Our fluorescent tracer detects microscopic metastases in real time during surgery and chemotherapy.
They trust us & support us
75% of patients relapse after first-line treatment.
Micrometastases escape the surgeon’s naked eye.
Annual cost of oncological relapse in Europe.
Injected locally just prior to surgery, our tracer selectively targets tumour biomarkers.
All metastases visualised, including microscopic ones. Compatible with NIR cameras already in use in the operating room — no additional equipment required.
The surgeon removes 100% of cancerous tissue in a single procedure.
Our tracer binds exclusively to tumour cells.
Live visualisation during surgery and/or real-time intraoperative guidance.
From micrometastases to primary tumours, across gynaecological and digestive cancers.
Preclinical validation complete; first-in-human trial (Phase I) in preparation.
Global intraoperative imaging market (2028)
Annual growth rate of the fluorescence segment.
Eligible oncological surgeries / year worldwide.
“ La chirurgie n'est efficace que si l'on retire la totalité de la charge tumorale. En présence de nombreuses adhérences abdominales, il est parfois difficile d'être sûr à 100 % d'avoir tout enlevé sans causer de dommages. Le traceur serait très utile pour s'assurer que tout a bien été retiré.”
“Après une chimiothérapie néoadjuvante, il est très difficile de distinguer visuellement le tissu tumoral du tissu cicatriciel. Si je vois une cicatrice sur l'intestin, je risque de pratiquer une résection intestinale inutile. Le traceur see2cure permettrait d'éviter ces résections "aveugles" et de ne traiter que les zones réellement tumorales.”
“ La chirurgie n'est efficace que si l'on retire la totalité de la charge tumorale. En présence de nombreuses adhérences abdominales, il est parfois difficile d'être sûr à 100 % d'avoir tout enlevé sans causer de dommages. Le traceur serait très utile pour s'assurer que tout a bien été retiré.”
“Après une chimiothérapie néoadjuvante, il est très difficile de distinguer visuellement le tissu tumoral du tissu cicatriciel. Si je vois une cicatrice sur l'intestin, je risque de pratiquer une résection intestinale inutile. Le traceur see2cure permettrait d'éviter ces résections "aveugles" et de ne traiter que les zones réellement tumorales.”
“La chirurgie guidée par fluorescence est un domaine qui pourrait nous aider à être beaucoup plus précis. Nous finissons souvent par retirer beaucoup de péritoine en excès par précaution face à des cicatrices suspectes. Un tel outil permettrait de réduire la morbidité liée à ces gestes inutiles. C’est le futur.”
“La chirurgie guidée par fluorescence est un domaine qui pourrait nous aider à être beaucoup plus précis. Nous finissons souvent par retirer beaucoup de péritoine en excès par précaution face à des cicatrices suspectes. Un tel outil permettrait de réduire la morbidité liée à ces gestes inutiles. C’est le futur.”
ScienceDirect
Academie sciences lettres Toulouse
GHP News digital
Founded See2Cure
Regulatory preclinical phase (industrial production and GLP non-clinical studies)
First-in-human trials – First indication: Advanced ovarian cancers
Phase IIa and international expansion
Peritoneal carcinomatosis is a common progression of digestive and gynaecological cancers affecting the abdomen. It occurs when cancerous cells detach from a primary tumour, spread, and reimplant throughout the abdominal cavity, giving rise to secondary tumours — also referred to as peritoneal metastases. Patient prognosis depends entirely on the completeness of surgical resection and, therefore, on the surgeon’s ability to remove all tumour deposits. However, a significant proportion of metastases are microscopic (under one millimetre) and escape detection during the procedure. This “invisible cancer” is responsible for high relapse rates. Currently, 75% of patients relapse following first-line treatment, and fewer than half survive five years after diagnosis. We address this challenge by delivering high-precision visualisation where the human eye reaches its limits.
Le traceur See2cure est un agent d’imagerie fluorescent conçu pour guider les chirurgiens en temps réel. Ce traceur intelligent combine une protéine capable de cibler un marqueur présent dans la plupart des cancers solides avec une molécule fluorescente.
Grâce aux caméras infrarouges déjà présentes dans les centres experts en oncologie, les zones malades deviennent visibles sur écran pendant l’intervention. Cette technologie permet de détecter les micrométastases (moins d’un millimètre) pour optimiser la chirurgie en la rendant beaucoup plus précise.
The primary indication for our fluorescent tracer is advanced ovarian cancer (stages 3 and 4) — one of the most aggressive malignancies in women and the leading cause of peritoneal metastasis. Over time, its use will be extended to other prevalent tumour types, including colorectal and gastric cancers. Our technology targets a specific biomarker — the Thomsen-Friedenreich antigen (CD176) — which offers two critical advantages: it is broadly expressed on the surface of cancer cells while remaining entirely absent from healthy tissue, enabling unambiguous tumour delineation; and it is present in nearly 80% of solid (epithelial) cancers, positioning our solution as a reference tool across a wide spectrum of oncological indications.
See2Cure is a biotech company spun out of French public research (CNRS and the Toulouse Oncopole). Since our founding in January 2024, we have reached key milestones: a seed funding round exceeding one million euros and the acquisition of an exclusive licence to commercialise our technology. We are currently in the regulatory preclinical phase — the pivotal stage preceding first-in-human trials — which encompasses two major workstreams: industrial-scale manufacturing of our tracer to clinical-grade standards, and the toxicology studies required by regulatory authorities to establish product safety. Our objective is to complete this dataset as rapidly as possible and initiate clinical trials in patients.
See2Cure stands apart through two major advances that redefine surgical diagnostic precision.
Ultra-early detection through locoregional injection
Most current tracers are administered intravenously and rely on the bloodstream to reach their target, limiting their efficacy to well-vascularised, established tumours. See2Cure’s tracer is injected directly into the abdominal cavity, bathing the surgical field and enabling the detection of cancerous foci at an extremely early stage — before they are even connected to the vascular system.
Signal clarity through tumour-specific targeting
Some existing tracers bind to markers also expressed, at low levels, in healthy tissue, generating false positives — areas that fluoresce in the absence of malignancy. See2Cure targets CD176, a biomarker present in 80% of solid cancers and entirely absent from healthy tissue, delivering a cleaner, more reliable intraoperative image and eliminating diagnostic ambiguity.
In short: See2Cure provides surgeons with a sharper, more trustworthy picture — revealing what was previously invisible while eliminating false signals from healthy tissue.
Please reach out via the form below to receive our Pitch Deck and speak directly with the team.
Our regulatory pathway is well-defined: preclinical validation is complete and the route to clinical trials is established.
Safety is subject to rigorous evaluation throughout our preclinical development programme and in forthcoming clinical trials.
Yes. Collaboration with healthcare industry stakeholders is a cornerstone of our strategy to integrate our technology into existing hospital infrastructure. Our immediate priority is bringing our fluorescent tracer to patients and surgeons as rapidly as possible, following a direct-to-clinic trajectory.
In parallel, we are preparing the next generation of our molecular targeting platform — including tumour-targeted chemotherapy and radiotherapy, currently at the R&D stage — and are actively seeking industrial partners in these areas. The goal is to combine the precision of our targeting technology with the expertise of established players in robotics, imaging and pharmaceuticals to co-develop the ultra-precise cancer treatments of tomorrow.
Investors, industrial partners, clinicians, let’s talk about the future of precision oncology.
